Merck Powering Up In Emerging Markets Through Alliance And Pricing Strategies
This article was originally published in PharmAsia News
Executive Summary
As Merck looks to expand its geographic footprint in emerging markets, local players with extensive distribution networks will be the focus for partnerships, Merck Chief Strategy Officer and former Emerging Markets R&D Head Mervyn Turner told investors at the CLSA Emerging Markets Pharma Conference Dec.1 in New York
You may also be interested in...
Tender, Tender On The Wall, What Lies Ahead For China In 2013?
The Chinese New Year is just around the corner, and many provinces are gearing up to initiate drug and high-end medical device tenders, leaving plenty for pharma and device executives to consider heading into 2013.
Will World's Largest HCV Population Have Access To Newest Treatments?
With a large patient pool and a recent expansion of government reimbursement for costly peg-interferon therapies, China is poised to see an exponential growth in its hepatitis C virus treatment market, growing north of 80% in five years, according to a recent report by research firm Decision Resources
Will World's Largest HCV Population Have Access To Newest Treatments?
With a large patient pool and a recent expansion of government reimbursement for costly peg-interferon therapies, China is poised to see an exponential growth in its hepatitis C virus treatment market, growing north of 80% in five years, according to a recent report by research firm Decision Resources